Sp1208
ENTEROCHROMAFFIN CELLS ARE CRITICAL DRIVERS OF VISCERAL PAIN
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Abdominal pain is one of the most common reasons for doctors visits, and presents in numerous GI diseases. Unfortunately the current treatment options targeting sensory neurons to reduce pain have limited efficacy or unwanted side effects, and this is especially true for visceral pain. Recent evidence strongly suggests that non-neuronal cell populations found in the gut, including epithelial cells, enteric glia, immune cells and gut microbiota, play major roles in visceral pain by directly interacting with sensory neurons that carry pain information. In this session, you will learn about how these 'unusual suspects' (i.e., non-neuronal cell types) are involved in visceral pain processes and and how manipulating their activity reduces hypersensitivity, inflammation, and other GI disease outcomes.
Abdominal pain is one of the most common reasons for doctors visits, and presents in numerous GI diseases. Unfortunately the current treatment options targeting sensory neurons to reduce pain have limited efficacy or unwanted side effects, and this is especially true for visceral pain. Recent evidence strongly suggests that non-neuronal cell populations found in the gut, including epithelial cells, enteric glia, immune cells and gut microbiota, play major roles in visceral pain by directly interacting with sensory neurons that carry pain information. In this session, you will learn about how these 'unusual suspects' (i.e., non-neuronal cell types) are involved in visceral pain processes and and how manipulating their activity reduces hypersensitivity, inflammation, and other GI disease outcomes.
Presenter
The University of North Carolina at Chapel Hill
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
INTRODUCTION
SOCIETY: AGA
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
